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1. Introduction 
The Y-box factors are a family of proteins that have been structurally and functionally 
conserved throughout evolution (Wolffe et al., 1992). They are transcription factors that are 
expressed in a wide range of cell types from bacteria to human cells. They are called Y-box 
proteins after the specificity originally shown for human YB-1 in binding the Y-box 
sequence CTGATTGGCCAA present in the promoter region of major histocompatibility 
complex class II genes (Didier et al., 1988). Y-box proteins have emerged as key players in 
cellular metabolism. These proteins are capable of binding one or more types of nucleic 
acids, single- or double-stranded DNA or RNA. The negative or positive modulation of 
transcription by YB-1 causes diverse biological effects on a wide array of genes, modification 
of chromatin (Ashizuka et al., 2002), translational masking of mRNA (Evdokimova et al., 
2006), cooperation in eukaryotic redox signaling pathways (Swamynathan et al., 2002), RNA 
chaperoning (Matsumoto et al., 2005) and stress response regulation (Swamynathan et al, 
1998). The nuclear functions of YB-1 also include a role in DNA replication (En-Nia et al., 
2005) and repair (Marenstein et al., 2001) as well as mRNA transport into the cytoplasm 
(Soop et al., 2003) (Figure 1). 
YB-1 protein is a member of the DNA-binding protein family. It binds to the Y-box, an 
inverted CCAAT box, in the promoter region of many oncogenes and regulates their 
activity, for example the human multidrug resistance 1 gene, which encodes P-glycoprotein 
(P-gp) (Kuwano et al., 2004; Gluz et al., 2009), the cell division cycle 6 gene, which promotes 
cell cycle progression (Basaki et al., 2010), and the membrane type I-matrix 
metalloproteinase, which facilitates tumor invasion and metastasis (Lovett et al., 2010).  
P-glycoprotein was first identified by virtue of its overexpression in multidrug resistant 
(MDR) tumor cells, where it mediates the energy-dependent efflux of a variety of 
chemotherapeutic agents (Trambas et al., 1997). The human class I P-glycoprotein is known 
to transport phospholipids, cholesterol, calcium channel blockers, immunosuppressants, 
peptides, steroids and xenobiotics (Bauer et al., 2005). More recent studies suggest that 
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Fig. 1. Involvement of Y-box proteins in various cellular processes 
upregulation of P-gp genes in tumor cells can prevent apoptosis and enhances the ability to 
resist chemotherapeutics (Park et al., 2006) and a wide range of apoptotic inducers, including 
serum starvation, fas ligand, UV irradiation, tumor necrosis factor and other stress inducer, 
including heat shock and chemotherapeutic agents (Hu et al., 2000). Gómez-Martínez has 
reported that the proximal promoter of MDR 1 contains several regulatory regions, 
including an inverted CCAAT box at -82 to -73 and a GC element at -56 to -42, both of which 
have been shown to be necessery for constitutive promoter activity in some cell types 
(Gómez-Martínez et al., 2007). Various environmental stimuli increase the activity of the 
MDR 1 promoter in response to all stimulation cascades that are dependent on the inverted 
CCAAT box (Kathleen & David, 1998). Interaction of the nuclear factor MDR-NF1 with this 
promoter region is increased when cells are exposed to UV or anticancer drugs (Ohga et al., 
1996). To understand the molecular basis of MDR 1 promoter activity and the stress-
dependent induction, the cDNA for MDR-NF1 has been cloned, revealing that the amino 
acid sequence encoded by the cloned cDNA is indentical to that of YB-1 (Ohga et al., 1996).  
YB-1 was found to be expressed at much higher levels in all cisplatin-resistant cell lines than 
in the respective drug-sensitive parental counterparts. Two transfectants with a YB-1 
antisense construct showed increased sensitivity to cisplatin, mitomycin C and UV 
irradiation, but not to vincristine, doxorubicin, camptothecin or etoposide, suggesting that 
cells with downregulated YB-1 gene expression are more sensitive to agents that induce 
cross-linking of DNA (Ohga et al., 1996). Nuclear localization and an upregulation of YB-1 
expression are closely associated with intrinsic MDR 1 gene expression in primary human 
breast cancers (Bargou et al., 1997; Spitkovsky et al., 1992). YB-1 protein is localized mainly 
in the cytoplasm, but accumulates in the nucleus by UV exposure, hyperthermia (Stein et al., 
2001), phosphorylation (Davies et al., 2011), or association with p53 (Zhang et al., 2003). This 
translocation may be induced by a protein kinase C-mediated signal transduction pathway, 
and the C-terminal region of YB-1 might be important for cytoplasmic retention of YB-1 
(Koike et al., 1997). Similarly, exposure to chemotherapeutic agents stimulates accumulation 
in the nucleus (Valiahdi et al., 2006).  
In malignant melanoma, YB-1 plays a key role for proliferation, survival and invasion and 
increases chemoresistance. The high expression of YB-1 in aggressive types of cancer and the 
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evidence for a role in cell proliferation suggests a potential as a therapeutic target. YB-1 also 
associates with key tumor factors such as MMP-2, bcl-2, cyclinD1 and p16INK4A (Schittek et 
al., 2007), p53 (Okamoto et al., 2000), AP-1 (Lasham et al., 2003), Smad 3 and p300 (Higashi 
et al., 2003) and directly as well as indirectly regulates gene expression. An increased YB-1 
expression of melanoma cells in comparison to benign melanocytes was shown in vitro and 
in vivo (Schittek et al., 2007). YB-1 is translocated into the nucleus in invasive and metastatic 
melanoma cells, and a downregulation of YB-1 by shRNA reduces the rate of proliferation 
and increases the rate of apoptotic cell death (Schittek et al., 2007). Translocation of the 
protein into the nucleus leads to its association with the family of serine/threonine kinases 
that inhibit apoptosis, stimulate angiogenesis, and promote tumor formation. It has also 
been suggested that Janus kinase and casein kinase II phosphorylate YB-1 and induce 
translocation of this protein into the nucleus (Sutherland et al., 2005).  
Gallium has long been studied for its suitability both for imaging and therapy of malignant 
tumors including melanoma among others, with the most prominent effects in malignant 
lymphoma (Jakupec & Keppler, 2004). Through never established in clinical routine, attempts 
to utilize gallium-67 scintigraphy for the detection and surveillance of occult metastatic 
disease in melanoma patients showed that these tumors can regularly be visualized by 
gallium tracers, suggesting a certain affinity (Kirkwood et al., 1982). To investigate the 
therapeutic effect of gallium nitrate in advanced malignant melanoma, a clinical study was 
performed in which gallium nitrate (250-300 mg/m2) was administered daily to 31 patients 
for 7 consecutive days. The compound was well tolerated, but only one of 31 evaluable 
patients experienced a partial remission (Casper et al., 1985). In a prior phase I study, 3 of 19 
patients with advanced melanoma treated with gallium nitrate had experienced disease 
stabilization (Bedikian et al., 1978). 
In order to improve the oral bioavailability and the pharmacological activity of gallium, a 
gallium complex has been developed by our institute (GaQ3). GaQ3 is an investigational 
anticancer drug in early clinical development, suitable for oral administration and well 
tolerable in toxicological studies (Collery et al., 1996). We demonstrated strong 
antiproliferative effects of GaQ3 in metastatic melanoma cell lines and in primary cultures of 
freshly explanted melanoma samples in comparison to established drugs (Valiahdi et al., 
2009). 
2. Experimental part  
2.1 Drugs 
Tris(8-quinolinolato)gallium (III) (GaQ3) was synthesized and isolated as a solid in high 
purity at the Institute of Inorganic Chemistry, University of Vienna, Austria, according to a 
previously established procedure (Collery et al., 1996). Gallium nitrate was purchased from 
Sigma-Aldrich as a hydrate of the composition Ga(NO3)3·5.8H2O, as determined by 
thermogravimetric analysis. GaQ3 was applied from fresh stock solutions in 
dimethylsulfoxide (DMSO) and diluted in media or buffer as appropriate to a maximum of 
0.3% DMSO. 
2.2 Cell lines and culture conditions  
The human melanoma cell lines 518A2, 607B, A375, MEL-JUSO and SK-MEL-28 were kindly 
provided by Dr. Rodrig Marculescu (Clinical Institute of Medical and Chemical Laboratory 
Diagnostics, Medical University of Vienna, Austria) and chicken embryo fibroblasts (Cef32) 
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by Prof. Dr. Wolfgang Schneider (Max F. Perutz Laboratories; Medical University of Vienna; 
Austria) , respectively. Cells were grown in 75 cm2 culture flasks (Iwaki/Asahi Technoglass, 
Gyouda, Japan) as adherent monolayer cultures in complete culture medium, i.e. minimal 
essential medium (MEM) supplemented with 10% heat-inactivated fetal bovine serum, 1 
mM sodium pyruvate, 4 mM L-glutamine and 1% non-essential amino acids (100×) (all 
purchased from Sigma–Aldrich, Vienna, Austria). Cultures were maintained at 37 °C in a 
humidified atmosphere containing 5% CO2. 
2.3 Cytotoxicity assay 
Cytotoxicity was determined by a colorimetric microculture assay (MTT assay). For this 
purpose, 518A2, 607B, A375, MEL-JUSO and SK-MEL-28 cells were harvested from culture 
flasks by trypsinization and seeded into 96-well microculture plates (Iwaki/Asahi 
Technoglass) in densities of 1.5–3.5 × 104 viable cells/well, depending on the cell line. After 
a 24 h preincubation, cells were exposed to dilutions of the test compounds in 200 μL/well 
complete culture medium for 96 h. At the end of exposure, drug solutions were replaced by 
100 μL/well RPMI 1640 medium (supplemented with 10% heat-inactivated fetal bovine 
serum and 4 mM L-glutamine) plus 20 μL/well MTT solution (5 mg/mL) in phosphate-
buffered saline (PBS) . After incubation for 4 h, medium was removed and the formazan 
product formed by viable cells was dissolved in DMSO (150 μL/well). Optical densities at 
550 nm were measured with a microplate reader (Tecan Spectra Classic). The quantity of 
viable cells was expressed in terms of T/C values by comparison to untreated controls, and 
50% inhibitory concentrations (IC50) were calculated from concentration-effect curves by 
interpolation. Evaluation is based on means from at least three independent experiments, 
each comprising six replicates per concentration level. 
2.4 Construction of plasmids expressing a GFP-YB-1 fusion protein 
Because of the high levels of endogenous YB-1 in the cells, it was useful to use tagged YB-1 
constructs for the study of YB-1. In this study, we developed a tagged chk-YB-1 by cloning 
cDNA of YB-1 into the ApaI site of the pEGFP-C1 plasmid. To investigate role of extreme C-
terminus of YB-1 on translocation into nucleus, the full-length YB-1 gene was deleted at the 
C-terminus to create the YB-1Δ27 product (Figure 2). 
 
1 51 129 321
GFP-YB-1
GFP-YB-1∆27
294
N-Term.                   CSD                                           C-Term.
GFP
GFP
N-Term.                    CSD                                           C-Term.
 
Fig. 2. Schematic representation of GFP-YB-1 and the truncated construct GFP-YB-1Δ27. The 
numbers represent the position of amino acids at the border between the respective 
domains. CSD: cold shock domain; GFP: green fluorescent protein 
2.5 Transient transfection  
Cef32 cells (chicken embryo fibroblasts) were transfected with a GFP-chk-YB-1, GFP-chk-
YB-1Δ27 or GFP only construct. SK-MEL-28 cells were transfected with a pCMV-YB-1-GFP 
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construct (kindly provided by Dr. K. Higashi, Kyoto University, Kyoto, Japan). In a six-well 
plate or 35-mm tissue culture plate, about 1-2 x 105 cells were seeded in 2 ml of MEM 
supplemented with 10% fetal calf serum and grown for 24 h to a confluence of 40-60%. The 
cells were washed once with 2 ml of serum-free medium, and for each transfection 0.8 ml 
serum-free medium were added to each tube containing 200 µl jetPEI reagent-DNA complex 
(Qbiogene, Inc). After washing, cells were overlaid with a 1 ml mixture of jetPEI reagent-
DNA complex and serum-free medium and incubated for 5-24 h at 37 °C. Then the DNA-
containing medium was replaced with 2 ml of growth medium containing serum and 
incubated for 48-72 h. In order to assure successful transfection, the expression of the 
reporter gene encoding for green fluorescence protein (GFP) was visualized directly by 
observation of green fluorescence under the fluorescence microscope or indirectly by an 
anti-GFP antibody (Western blotting). 
2.6 Nuclear and cytoplasmic cell extracts 
To obtain total cell extracts, Cef32 cells were washed twice in PBS, scraped into PBS, 
pelleted, and resuspended in lysis buffer. Cells were washed with PBS, resuspended in 200 
µl ice-cold 40% TKM buffer (50 mM Tris-HCl pH 7.4, 25 mM KCl, 5 mM MgCl2, 0.2 mM 
EDTA) containing protease inhibitor (1 M dithiothreito (DTT), 10 mM vanadate, 1 mg/ml 
leupeptin, 3 mg/ml aprotinin and 100 mM phenylmethylsulfonylfluorid (PMSF)) and 
incubated on ice for 10 min. Then, the cells were disrupted by 25 strokes in a dounce 
homogenizer using a tight-fitting pestle. The homogenate was immediately diluted with the 
threefold volume of TKM buffer and centrifuged at 1000xg for 10 min at 4 °C. The low-speed 
supernatant was used as the cytoplasmic fraction. The low-speed pellet was resuspended in 
400 µl TKM buffer, laid on 400 µl 60% sucrose in TKM and centrifuged at 100.000xg for 60 
min at 4 °C. The sucrose was aspirated and the pellet (nuclear fraction) resuspended in 800 
µl TKM buffer. 
2.7 Western blotting 
Western blots of both nuclear extracts and cytosolic fractions of untreated and UV-exposed 
Cef32 cells were assayed by immunoblotting using anti-chk-YB-1C (1:5000 dilution, Sigma) 
and primary antibodies against GFP (1:1000) (mouse IgG monoclonal antibody, clones 7.1 
and 13.1, Roche). For this purpose, Cef32 cells and Cef32 cells transiently expressing EGFP-
chk-YB-1 were treated with UV light (50 J/m2), and whole cell lysates or fractionated cell 
lysates were diluted in 2x sample buffer (125 mM Tris pH 6.8, 4% sodium dodecyl sulfate 
(SDS), 10% glycerol, 0.006% bromophenol blue, 1.8% beta-mercaptoethanol). Denatured 
cellular extracts were resolved by SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel 
electrophoresis), transferred onto nitrocellulose membranes (Amersham Hybond ECL, GE 
Healthcare, Little Chalfont, UK), blocked in fetal calf serum, and incubated with appropriate 
antibodies. Secondary anti-mouse antibody was used in dilutions of 1:10000. For 
visualization of the proteins, Western blotting luminal reagent (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) was used according to the instructions of the manufacturer, and X-
ray film was exposed to the blots. 
2.8 UV irradiation 
Cef32 cells were grown in MEM medium to 80% confluence. The medium was removed and 
the cells were washed with PBS (37 °C). After treatment of the cells with UV light at 50 J/m2 
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(UV Stratalinker 2400), the removed medium was added again to the cells and cells were 
incubated for 1 hour at 37 °C. The effect of UV irradiation was investigated either by using 
fluorescence microscopy or Western blotting. 
3. Results  
Cytotoxicity in melanoma cell lines  
The IC50 values obtained with GaQ3 in five human melanoma cell lines are in a relatively 
narrow range of very low micromolar concentrations (0.8–2.5 µM), whereas cytotoxicity of 
the former investigational anticancer drug gallium nitrate is much lower, as reflected by IC50 
values between 20 and > 200 µM in the same cell lines (Table 1, Figure 3). Thus, GaQ3 shows 
a 23- to > 80-fold higher potency than gallium nitrate, based on the comparison of IC50 
values. The high intrinsic gallium nitrate resistance of the cell line SK-MEL-28 does not 
affect sensitivity to GaQ3 in equal measure. 
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Fig. 3. Comparison of concentration-effect curves of GaQ3(–t–) and gallium nitrate (–▲–) in 
the human melanoma cell lines 518A2 (A), 607B (B), A375 (C), MEL-JUSO (D) and SK-MEL-28 
cells (E), obtained by the MTT assay (96 h exposure) 
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Compound IC50 (μM)a 
 SK-MEL-28 607B A375 MEL-JUSO 518A2 
GaQ3 2.45 ± 0.15 1.35 ± 0.09 1.30 ± 0.15 1.05 ± 0.10 0.855 ± 
0.362 
Gallium 
nitrate 
> 200 39.9 ± 4.7 72.4 ± 8.9 42.7 ± 9.1 20.0 ± 1.0 
a 50% inhibitory concentrations in SK-MEL-28, 607B, A375, MEL-JUSO and 518A2 melanoma cells in the 
MTT assay, 96h exposure. Values are the mean ± standard deviation obtained from at least three 
independent experiments.  
Table 1. Cytotoxicity of the new gallium complex (GaQ3) in comparison with gallium nitrate 
in five human melanoma cell lines 
Immunostaining 
Preliminary experiments showed that the chk-YB-1C antibody was unable to detect the 
fusion YB-1 protein, presumably due to steric hindrance. Therefore, exogenous YB-1 
expression in GFP-YB-1 transfected Cef32 cells (in comparison with GFP-only-transfected 
cells) were indirectly detected by an anti-GFP antibody (Figure 4). The expression of the 
fusion protein GFP-YB-1 with a molecular weight of 77 kDa is clearly discernible in the 
immunoblots of total Cef32 cell extracts. 
 
Untransfected GFP-only GFP-YB-1 
77 kDa
27 kDa
 
Fig. 4. Western blot of total cell extracts from Cef32 cells transiently transfected with GFP 
and GFP-YB-1, as well as from untransfected cells (negative control). Proteins were 
separated on a 10%polyacrylamide SDS gel and probed with anti-GFP antibody (1:5000 
dilution) 
The effect of UV irradiation on the localization of endogenous and exogenous chk-YB-1 in 
Cef32 cells was studied with an antibody directed against the extreme C-terminus of YB-1 
(anti-chk-YB-1C), revealing that the endogenous protein in UV-exposed cells can be found 
in the nuclear fraction after only 1 hour incubation (Figure 5, middle blots). To indicate the 
exogenous YB-1 protein in Cef32 cells, we detected the presence of the GFP fusion protein in 
the nuclear fraction after UV irradiation by an anti-GFP polyclonal antibody, revealing the 
same nuclear translocation for the exogenous YB-1 protein upon UV exposure (Figure 5, 
upper blot).  
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Fig. 5. Subcellular distribution of endogenous and exogenous YB-1 protein in Cef32 cells. 
Western blots of both nuclear extracts and cytosolic fractions of untreated and UV-exposed 
(50 J/m2) untransfected and transfected Cef32 cells were assayed by immunoblotting using 
anti-GFP antibody (upper blots) and anti-chk-YB-1C antibody (middle blots). In order to 
exclude contamination of the nuclear fraction with cytosolic proteins, extracts were 
immunoblotted with anti-α-tubulin (lower blot) 
Fluorescence microscopy 
The subcellular distribution of GFP-YB-1 and the effect of UV irradition were additionally 
investigated by fluorescence microscopy of Cef32 cells transfected with the chk-YB-1-GFP 
expression construct, yielding further evidence for the nuclear accumulation of YB-1 upon 
UV irradiation, whereas larger amounts of YB-1 were detected in the cytosol, more at the 
perinuclear region than in the nucleus of untreated fibroblast cells (Figure 6).  
 
A 
B C D 
 
Fig. 6. Fluorescence microscopic images of Cef32 cells transfected with either pEGFP-C1 
only (A) or a GFP-chk-YB-1 construct (B-D). While the fluorescence of GFP is rather evenly 
distributed in both cytosol and nucleus in the former cells (no difference of GFP expression 
in cytoplasm and nucleus) (A), untreated GFP-chk-YB-1 transfected cells show mainly 
cytosolic fluorescence, indicating the cytosolic expression of YB-1 (B, D). Translocation of 
this protein into the nucleus was observed 2 h after UV irradiation (50 J/m2) (C) 
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To investigate the effect of the deletion of the 27 C-terminal amino acids on intracellular 
localization of YB-1, GFP-YB-1(27 was transfected transiently into Cef32 cells and visualized 
by fluorescence microscopy after 48 hours incubation at 37 °C. GFP-YB-1 and GFP-YB-1(27 
lacking the C-terminus (294-321) of YB-1 were located mainly in the cytosol, but the deletion 
construct was located more in perinuclear regions (Figure 7 B). In contrast to cells 
transfected with the complete GFP-YB-1 construct, UV irradiation did not result in 
recognizable nuclear translocation of fluorescence in those cells transfected with the deletion 
construct (Figure 7C), suggesting that the C-terminal sequence is essential for translocation. 
 
A CB
 
Fig. 7. Fluorescence microscopic images of Cef32 cells transiently transfected with GFP-YB-1 
(A) or GFP-YB-1Δ27 (B, C). The deletion product GFP-YB-1Δ27 is mainly expressed in the 
cytosol, in particular in the perinuclear region, in untreated cells (B), and no pronounced 
translocation into the nucleus is discernible upon UV irradiation (50 J/m2) (C) 
Furthermore, the human melanoma cell line SK-MEL-28 was transfected with a pCMV-hYB-
1-GFP plasmid (encoding for human YB-1), and the localization of YB-1 in the cell was again 
visualized using the fluorescence of the reporter protein GFP. The same translocation of YB-
1 into the nucleus as in UV-treated Cef32 cells was observed upon GaQ3 treatment in these 
transiently transfected SK-MEL-28 cells (Figure 8). 
 
 A C B 
 
Fig. 8. Fluorescence microscopic images of SK-MEL-28 cells transiently transfected with 
pCMV-YB-1-GFP construct. Untreated cells show mainly a cytosolic expression of YB-1 (A), 
whereas translocation into the nucleus is visible after treatment with 5 µM GaQ3 for 24 h (B,C) 
4. Discussion 
The tumor-inhibiting compound GaQ3 has strong antiproliferative activity in human 
melanoma cells, in particular in the Human Tumor Cloning Assay (HTCA) in primary 
melanoma explants. The effects induced by GaQ3 in melanoma cell lines involve S phase 
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arrest, caspase activation and poly-(ADP-ribose) polymerase cleavage, indicating induction 
of apoptosis, whereas no direct interactions with DNA could be observed (Valiahdi et al., 
2009). The improved pharmacological properties of GaQ3 as compared to earlier gallium-
based agents and in vitro data presented here warrant further studies of this compound in 
malignant melanoma. The mechanism of action of GaQ3 is far from understood, but seems 
to deviate from that of gallium nitrate and does not involve DNA interactions such as cross-
linking or strand breakage (Valiahdi et al., 2009). Nevertheless, we could demonstrate that 
cellular responses to this investigational anticancer drug involve the Y-box protein YB-1.  
Y-box proteins play multiple roles in the cell, serving as transcription factors, as a part of 
mRNA particles, or in cell proliferation (Matsumoto & Wolffe, 1998); however, their entire 
function is still unclear. The import of transcription factors into the nucleus is not a 
constitutive process and appears to be modulated in response to external stimuli, cell cycle 
and development. Regulation of the subcellular localization of proteins involves the direct 
phosphorylation of the transported protein, masking of the nuclear localization signals, 
cytoplasmic retention by binding to an anchoring protein, and the interplay among these 
different mechanisms (Calkhoven & Ab, 1996; Garcia-Bustos et al., 1991). It has been 
proposed that the YB-1 protein migrates to the nucleus in response to certain stress signals 
(Koike et al., 1997). However, examination of the YB-1 sequence shows no obvious nuclear 
localisation sequence. The question arising from this issue is: How are Y-box proteins 
signalized to move into the nucleus? Is phosphorylation an effective factor for nuclear 
translocation? To address this issue, we considered possibilities to tag the protein to study 
compartimental changes and to investigate what region of the protein might be responsible 
for this translocation. A GFP fusion protein enabled us to observe the subcellular location 
and intracellular movements in vitro. Observations under the fluorescence microscope 
showed clearly a predominant expression of GFP-YB-1 and the truncated version YB-1(27 in 
the cytoplasm of Cef32 cells. Kokie and colleagues have reported that the C-terminal region 
of YB-1 might be important for cytoplasmic retention of YB-1. In their study, they 
demonstrated that expression of GFP-YB-1 with the C-terminus of YB-1 was located mainly 
in the cytosol, but GFP-YB-1deltaC with a larger deletion at the C-terminus of YB-1 (248-317) 
was located in the nucleus (Kokie et al., 1997), in contrast to our observation with a different 
deletion at the C terminus. The C-terminal domain of YB-1 does not have a nuclear export 
signal such as mitogen activated protein kinase kinase (MAPKK). Since this domain has 
been shown to be involved in the protein-protein interaction, it was hypothesized that YB-1 
could be retained in the cytoplasm by binding to an anchoring protein (Ruzanov et al., 
1999), as observed for the transcription factor NF-κB interacting with I κB in the cytoplasm 
(Verma et al., 1995).  
The recruitment of YB-1 to the nucleus after exposure to UV irradiation or cytotoxic agents 
suggests that YB-1 itself protects the cells against the effects of genotoxic damage (Cohen et 
al., 2010). The association between nuclear YB-1 and resistance against cisplatin might be a 
useful predictive marker for cancer multidrug resistance (Yahata et al., 2002). Recently, an 
association of YB-1 interacellular localization with expression levels of P-gp (P-glycoprotein, 
which is able to dispose drugs from the cell via the cell membrane) has been proposed 
(Bargou et al., 1997). This P-glycoprotein is encoded by the MDR1 gene, which responsible 
for drug resistance of many tumors. Bargou have reported that nuclear localization of YB-1 
is closely associated with MDR1 gene expression in a human breast cancer cell line and that 
P-gp levels were high in untreated primary breast cancers in which YB-1 was localized in 
the nucleus, but were low in the breast cancers where YB-1 was localized in the cytoplasm. 
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These results show that in untreated primary breast cancers, nuclear localization of YB-1 
protein is associated with intrinsic multidrug resistance. It was shown that YB-1 has an 
important role in controlling MDR 1 gene transcription, and this finding provides a basis for 
the analysis of molecular mechanisms responsible for intrinsic multidrug resistance in 
human breast cancer. However, it remains unclear whether activated YB-1 directly affects 
MDR1 gene expression in response to genotoxic stress. In previous studies suggests that YB-
1 may itself have a key role in self-defense signaling mechanisms, being initiated in response 
to cellular stress. The YB-1 proteins are also integral components of a eukaryotic redox 
signalling pathway (Duh et al., 1995), serving as a scaffold for the assembly of other factors. 
All this information indicates that these Y-box proteins may be a part of mammalian stress 
signal transduction mechanisms. 
In our studies, we investigated the dependence of intercellular localization of human-YB-1 
and chk-YB-1 in metastatic melanoma cells and chicken embryo fibroblasts, respectively, by 
stress factors such as UV irradiation and GaQ3 treatment. Furthermore, we demonstrated 
that the last 27 amino acids of the C-terminus are necessary for translocation of the protein 
into the nucleus, since this deletion (YB-1Δ27 (294-321)) correlated with an inhibition of 
nuclear translocation after UV irradiation. This sequence (27 amino acids) which is rich in 
SH groups is a suitable substrate for posttranslational modification, in particular 
phosphorylation by protein kinases at serine or threonine. The frequency of these amino 
acids increases the negative charge of the acidic sequences and probably improves the 
interaction of the C-terminal domain with other proteins (carrier proteins). Protein-protein 
interactions may be the cause of migration of chkYB-1 into the nucleus. Molecular 
intervention aiming at the inhibition of nuclear translocation of YB-1 may be a strategy to 
improve the efficacy of anticancer drugs.  
In conclusion, nuclear localization of YB-1 is a cellular response to damaging agents such as 
UV irradiation or the investigational anticancer drug GaQ3. YB-1 itself may be worth 
investigating as a potential target in cancer therapy, in particular in combination with 
cytotoxic drugs in malignant melanoma. 
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